{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T19:34:44Z","timestamp":1696966484276},"reference-count":21,"publisher":"Elsevier BV","issue":"17-18","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.vaccine.2003.11.040","type":"journal-article","created":{"date-parts":[[2003,12,19]],"date-time":"2003-12-19T12:15:03Z","timestamp":1071836103000},"page":"2278-2284","source":"Crossref","is-referenced-by-count":6,"title":["Immunisation schedules for non-replicating nasal vaccines can be made simple by allowing time for development of immunological memory"],"prefix":"10.1016","volume":"22","author":[{"given":"Hilde","family":"Bakke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torhild N.","family":"Setek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phuong N.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inger Lise","family":"Haugen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.Arne","family":"H\u00f8iby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Holst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingeborg S.","family":"Aaberge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rn","family":"Haneberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2003.11.040_BIB1","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/IAI.66.4.1334-1341.1998","article-title":"Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans","volume":"66","author":"Haneberg","year":"1998","journal-title":"Infect. Immun."},{"key":"10.1016\/j.vaccine.2003.11.040_BIB2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1128\/IAI.67.2.921-927.1999","article-title":"Antigen-specific T-cell responses in humans after intranasal immunisation with a meningococcal serogroup B outer membrane vesicle vaccine","volume":"67","author":"Oftung","year":"1999","journal-title":"Infect. Immun."},{"key":"10.1016\/j.vaccine.2003.11.040_BIB3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1046\/j.1365-2273.1998.00173.x","article-title":"Mucociliary transport and its assessment: a review","volume":"23","author":"Lale","year":"1998","journal-title":"Clin. Otolaryngol."},{"key":"10.1016\/j.vaccine.2003.11.040_BIB4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1046\/j.1365-2273.1997.00019.x","article-title":"The nasal delivery of drugs","volume":"22","author":"Quaraishi","year":"1997","journal-title":"Clin. Otolaryngol."},{"key":"10.1016\/j.vaccine.2003.11.040_BIB5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0264-410X(99)00216-9","article-title":"Safety and immunogenicity of intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers","volume":"18","author":"Drabick","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2003.11.040_BIB6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0264-410X(94)90112-0","article-title":"New strategies for using mucosal vaccination to achieve more effective immunisation","volume":"12","author":"Walker","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2003.11.040_BIB7","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S0264-410X(97)00064-9","article-title":"A nasal whole-cell pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin","volume":"15","author":"Berstad","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2003.11.040_BIB8","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0264-410X(97)00021-2","article-title":"Nasal immunisation with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice","volume":"15","author":"Hordnes","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2003.11.040_BIB9","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1016\/S0264-410X(99)00046-8","article-title":"Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice","volume":"17","author":"Dalseg","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2003.11.040_BIB10","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1128\/IAI.67.9.4320-4325.1999","article-title":"Intranasal immunisation with heat-inactivated Streptococcus pneumoniae protects against systemic pneumococcal infection","volume":"67","author":"Hvalbye","year":"1999","journal-title":"Infect. Immun."},{"key":"10.1016\/j.vaccine.2003.11.040_BIB11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0264-410X(03)00558-9","article-title":"Bordetella pertussis can act as adjuvant as well as inhibitor of immune responses to non-replicating nasal vaccines","volume":"22","author":"Haugan","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2003.11.040_BIB12","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1128\/IAI.69.8.5010-5015.2001","article-title":"Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance","volume":"69","author":"Bakke","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.vaccine.2003.11.040_BIB13","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Fredriksen","year":"1991","journal-title":"NIPH Ann."},{"key":"10.1016\/j.vaccine.2003.11.040_BIB14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1128\/IAI.62.1.15-23.1994","article-title":"Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina, measured by a new method for collection of secretions from local mucosal surfaces","volume":"62","author":"Haneberg","year":"1994","journal-title":"Infect. Immun."},{"key":"10.1016\/j.vaccine.2003.11.040_BIB15","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1128\/IAI.60.10.4146-4153.1992","article-title":"Scid-hu mice immunised with a pneumococcal vaccine produce specific human antibodies and show increased resistance to infection","volume":"60","author":"Aaberge","year":"1992","journal-title":"Infect. Immun."},{"key":"10.1016\/j.vaccine.2003.11.040_BIB16","first-page":"147","article-title":"Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey","volume":"14","author":"H\u00f8iby","year":"1991","journal-title":"NIPH Ann."},{"key":"10.1016\/j.vaccine.2003.11.040_BIB17","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1128\/IAI.63.12.4642-4652.1995","article-title":"Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine","volume":"63","author":"Rosenqvist","year":"1995","journal-title":"Infect. Immun."},{"key":"10.1016\/j.vaccine.2003.11.040_BIB18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","article-title":"Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland","volume":"177","author":"Perkins","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2003.11.040_BIB19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/14760584.1.2.227","article-title":"Can nonliving nasal vaccines be made to work?","volume":"2","author":"Haneberg","year":"2002","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.vaccine.2003.11.040_BIB20","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/0264-410X(93)90363-3","article-title":"Protection of mice against respiratory Bordetella pertussis infection by intranasal immunisation with P.69 and FHA","volume":"11","author":"Roberts","year":"1993","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2003.11.040_BIB21","unstructured":"Watson JC, Peter G. General immunization practices. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. London: WB Saunders Company; 1999. p. 47\u201373."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X03008417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X03008417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T07:02:08Z","timestamp":1585378928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X03008417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":21,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0264410X03008417"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2003.11.040","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}